Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective randomized controlled study of early intravitreal bevacizumab for severe central retinal vein occlusion
2009-017735-18Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in central retinal vein occlusion (CRVO) (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Visual acuity gain at 6 months. Started Apr 2010; status: active.
02
Drugs
bevacizumab
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2009-017735-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017735-18.